© Reuters. Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage

By Jan Wolfe

(Reuters) – Bristol-Myers Squibb (NYSE:) Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc (NASDAQ:) in a U.S. patent dispute relating to technology for treating cancer.

A jury in Los Angeles awarded the damages after finding that Yescarta, a treatment sold by Gilead’s Kite Pharma unit, infringed on a patent exclusively licensed by Bristol-Myers’ Juno Therapeutics division.

The patent at issue in the lawsuit, which Juno licenses from the Memorial Sloan Kettering Cancer Center in New York, relates to CAR T-cell immunotherapy for cancer.

CAR-T therapy involves a process of removing T cells from a patient’s immune system, engineering them to better identify and attack cancer cells and infusing them back into the patient.

Bristol-Myers said in a statement that it was pleased with the verdict.

Gilead disagreed with the decision.

“We remain steadfast in our opinion that Sloan Kettering’s patent is not infringed and is invalid,” Gilead said in a statement. “Given that Kite independently developed Yescarta and assumed all of the risk in its discovery and development, we do not believe Sloan Kettering and Juno are entitled to any level of damages.”

Gilead said it expected to seek to undo the verdict through post-trial motions and an appeal.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

2019-12-13